Devonian Reports 2024 Annual Financial Results
Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical-stage botanical pharmaceutical company specializing in the development of unique botanical pharmaceutical and cosmeceutical products, has announced its financial…
Generic Injectables Market Report 2024-2030: Patent Expirations and New Opportunities
The global Generic Injectables market, valued at $95.2 billion in 2023, is on a strong growth trajectory and is projected to reach $206.8 billion by 2030, growing at a CAGR…
Bayer Expands Global Incubator Network with Co.Lab Berlin, Welcomes MyoPax as First Resident
Bayer has inaugurated Bayer Co.Lab Berlin, a state-of-the-art life science incubator located at the company’s Pharmaceuticals Division Global Headquarters Campus. Positioned near leading research and clinical institutions in Berlin, the…
UCB Advances New Launches and Divests Mature Product Business in China
UCB, a global biopharmaceutical leader, has announced the successful completion of its sale, divestment, and licensing agreement for its mature neurology and allergy portfolio in China. The transaction, valued at…
EU Approves BeiGene’s TEVIMBRA for Advanced Esophageal and Gastric Cancer Treatment
BeiGene has announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with chemotherapy as a first-line treatment for two aggressive cancer types: esophageal squamous cell carcinoma (ESCC) and…
New Report Urges Continued Investment in Infection Prevention Programs
Nearly five years after the onset of COVID-19, a new report from the World Health Organization (WHO) reveals limited progress in closing critical gaps in infection prevention and control (IPC)…
Dr. Reddy’s Launches Toripalimab in India, First Immuno-Oncology Drug for Nasopharyngeal Carcinoma
Dr. Reddy’s Laboratories Ltd has announced the launch of Toripalimab in India, marking a significant advancement in the treatment of nasopharyngeal carcinoma (NPC). Toripalimab, a New Biological Entity (NBE), is…
Global Head and Neck Cancer Therapeutics Market: 2024 Overview and 2030 Forecast
The global market for head and neck cancer therapeutics is estimated to reach $1.7 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of…
Altasciences Partners with Metsera to Advance Early-Stage Clinical Trials for Obesity Treatment
Altasciences, a full-service early-phase contract research organization, is proud to have partnered with Metsera, Inc., a clinical-stage biopharmaceutical company dedicated to advancing next-generation therapies for obesity and metabolic diseases. This…
New Guidance for Sustainable, Climate-Resilient Healthcare Facilities
The World Health Organization (WHO) has published a new report titled Safe, Climate-Resilient, and Environmentally Sustainable Healthcare Facilities: An Overview. This guide offers policymakers, health administrators, facility managers, and healthcare…
Second IHR Emergency Meeting on Mpox Surge 2024
The Director-General of the World Health Organization (WHO) has released the report from the second meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the mpox outbreak of…
Genentech Shares Latest Findings from Phase III SKYSCRAPER-01 Study
Genentech, part of the Roche Group, has provided an update on the Phase III SKYSCRAPER-01 study, which evaluated the combination of tiragolumab with Tecentriq® (atezolizumab) compared to Tecentriq alone in…